Picture of blood cells

Open Access research which pushes advances in bionanotechnology

Strathprints makes available scholarly Open Access content by researchers in the Strathclyde Institute of Pharmacy & Biomedical Sciences (SIPBS) , based within the Faculty of Science.

SIPBS is a major research centre in Scotland focusing on 'new medicines', 'better medicines' and 'better use of medicines'. This includes the exploration of nanoparticles and nanomedicines within the wider research agenda of bionanotechnology, in which the tools of nanotechnology are applied to solve biological problems. At SIPBS multidisciplinary approaches are also pursued to improve bioscience understanding of novel therapeutic targets with the aim of developing therapeutic interventions and the investigation, development and manufacture of drug substances and products.

Explore the Open Access research of SIPBS. Or explore all of Strathclyde's Open Access research...

A novel therapeutic approach to cytokine modulation in articular inflammation using filarial nematode derived ES-62

McInnes, I.B. and Gracie, J.A. and Leung, B.P. and Harnett, M.M. and Liew, F.Y. and Harnett, W. (2003) A novel therapeutic approach to cytokine modulation in articular inflammation using filarial nematode derived ES-62. Arthritis Research and Therapy, 5 (Suppl ). p. 52. ISSN 1478-6354

Full text not available in this repository.Request a copy from the Strathclyde author

Abstract

Discovering safe, novel immunomodulators that are effective in RA is currently a major therapeutic objective. Long-term immune system deviation is most striking in the host-parasite relationship, in which microbes may coexist with a human host. ES-62 exhibited powerful immunomodulation of CIA, preventing initiation of inflammatory arthritis. Crucially, ES-62 suppressed even established disease. These effects were due to inhibition of cytokine release, specifically TNF-α, and reversal of collagen specific Th1 responses associated with reduced expression of IFN-γ. The physiologic relevance of these observations was confirmed, as ES-62 down-regulated the release of proinflammatory cytokines (TNF-α and IL-6) from patient-derived samples.